Biogen (BIIB) Remains Buy at Deutsche Bank Ahead of Nov. Tecfidera EU Decision
Tweet Send to a Friend
Deutsche Bank today maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $270.00. Comments follow Q3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
